Full Text of HB4707 100th General Assembly
HB4707 100TH GENERAL ASSEMBLY |
| | 100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018 HB4707 Introduced , by Rep. Sue Scherer SYNOPSIS AS INTRODUCED: |
| 225 ILCS 80/15.1 | | 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 | 720 ILCS 570/206 | from Ch. 56 1/2, par. 1206 |
|
Amends the Illinois Controlled Substances Act. Changes the classification of Hydrocodone from a Schedule II controlled substance to a Schedule I controlled substance. Amends the Illinois Optometric Practice Act of 1987 to make a conforming change.
|
| |
| | | CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY | |
| | A BILL FOR |
|
| | | HB4707 | | LRB100 16559 RLC 31691 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Optometric Practice Act of 1987 is | 5 | | amended by changing Section 15.1 as follows:
| 6 | | (225 ILCS 80/15.1)
| 7 | | (Section scheduled to be repealed on January 1, 2027)
| 8 | | Sec. 15.1. Diagnostic and therapeutic authority.
| 9 | | (a) For purposes of the Act, "ocular pharmaceutical
agents" | 10 | | means topical anesthetics, topical mydriatics, topical
| 11 | | cycloplegics, topical miotics and mydriatic reversing agents, | 12 | | anti-infective agents,
anti-allergy agents,
anti-glaucoma | 13 | | agents (except oral carbonic anhydrase inhibitors, which may be | 14 | | prescribed only in a quantity sufficient to provide treatment | 15 | | for up to 30 days),
anti-inflammatory agents (except oral | 16 | | steroids, which may be prescribed only in a quantity sufficient | 17 | | to provide treatment for up to 7 days), over-the-counter | 18 | | agents, analgesic
agents, anti-dry eye agents, and agents for | 19 | | the treatment of hypotrichosis. | 20 | | (a-3) In addition to ocular pharmaceutical agents that fall | 21 | | within the categories set forth in subsection (a) of this | 22 | | Section, the Board may add a pharmaceutical agent approved by | 23 | | the FDA or class of agents for the purpose of the diagnosis or |
| | | HB4707 | - 2 - | LRB100 16559 RLC 31691 b |
|
| 1 | | treatment of conditions of the eye and adnexa after | 2 | | consideration of the agent's systemic effects, side effects, | 3 | | and the use of the agent within the practice of optometry. The | 4 | | Board shall consider requests for additional agents and make | 5 | | recommendations within 90 days after the receipt of the | 6 | | request. | 7 | | Within 45 days after the Board's recommendation to the | 8 | | Department of a pharmaceutical agent or class of agents, the | 9 | | Department shall promulgate rules necessary to allow for the | 10 | | prescribing or administering of the pharmaceutical agent or | 11 | | class of agents under this Act. | 12 | | (a-5) Ocular pharmaceutical agents administered by | 13 | | injection may be used only for the treatment of anaphylaxis. | 14 | | (a-10) Oral pharmaceutical agents may be prescribed for a | 15 | | child under 5 years of age only in consultation with a | 16 | | physician licensed to practice medicine in all its branches. | 17 | | (a-15) The authority to prescribe a Schedule III, IV, or V | 18 | | controlled substance shall include analgesic agents only in a | 19 | | quantity sufficient to provide treatment for up to 72 hours. | 20 | | The prescription of a Schedule II controlled substance is | 21 | | prohibited , except for Dihydrocodeinone (Hydrocodone) with one | 22 | | or more active, non-narcotic ingredients only in a quantity | 23 | | sufficient to provide treatment for up to 72 hours, and only if | 24 | | such formulations of Dihydrocodeinone are reclassified as | 25 | | Schedule II by federal regulation .
| 26 | | (b) A licensed optometrist may remove superficial foreign |
| | | HB4707 | - 3 - | LRB100 16559 RLC 31691 b |
|
| 1 | | bodies from the human eye and adnexa and may give orders for | 2 | | patient care to a nurse or other health care provider licensed | 3 | | to practice under Illinois law.
| 4 | | (c) An optometrist's license shall be revoked or suspended | 5 | | by the Department
upon recommendation of the Board based upon | 6 | | either of the
following causes: | 7 | | (1) grave or repeated misuse of any ocular
| 8 | | pharmaceutical agent; and | 9 | | (2) the use of any agent or procedure in the course of | 10 | | optometric practice
by an optometrist not properly | 11 | | authorized under this Act. | 12 | | (d) The Secretary of Financial and Professional Regulation | 13 | | shall notify
the Director of Public Health as to the categories | 14 | | of ocular
pharmaceutical agents permitted for use by an | 15 | | optometrist. The Director of Public Health shall in turn
notify | 16 | | every licensed pharmacist in the State of the categories of | 17 | | ocular
pharmaceutical agents that can be utilized and | 18 | | prescribed by an optometrist.
| 19 | | (Source: P.A. 98-1111, eff. 8-26-14; 99-909, eff. 1-1-17.)
| 20 | | Section 10. The Illinois Controlled Substances Act is | 21 | | amended by changing Sections 204 and 206 as follows: | 22 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 23 | | Sec. 204. (a) The controlled substances listed in this | 24 | | Section are
included in Schedule I. |
| | | HB4707 | - 4 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (b) Unless specifically excepted or unless listed in | 2 | | another
schedule, any of the following opiates, including their | 3 | | isomers,
esters, ethers, salts, and salts of isomers, esters, | 4 | | and ethers,
whenever the existence of such isomers, esters, | 5 | | ethers and salts is
possible within the specific chemical | 6 | | designation: | 7 | | (1) Acetylmethadol; | 8 | | (1.1) Acetyl-alpha-methylfentanyl | 9 | | (N-[1-(1-methyl-2-phenethyl)-
| 10 | | 4-piperidinyl]-N-phenylacetamide); | 11 | | (2) Allylprodine; | 12 | | (3) Alphacetylmethadol, except
| 13 | | levo-alphacetylmethadol (also known as levo-alpha-
| 14 | | acetylmethadol, levomethadyl acetate, or LAAM); | 15 | | (4) Alphameprodine; | 16 | | (5) Alphamethadol; | 17 | | (6) Alpha-methylfentanyl
| 18 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 19 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 20 | | propanilido) piperidine; | 21 | | (6.1) Alpha-methylthiofentanyl
| 22 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 23 | | 4-piperidinyl]-N-phenylpropanamide); | 24 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 25 | | (7.1) PEPAP
| 26 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
| | | HB4707 | - 5 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (8) Benzethidine; | 2 | | (9) Betacetylmethadol; | 3 | | (9.1) Beta-hydroxyfentanyl
| 4 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 5 | | 4-piperidinyl]-N-phenylpropanamide); | 6 | | (10) Betameprodine; | 7 | | (11) Betamethadol; | 8 | | (12) Betaprodine; | 9 | | (13) Clonitazene; | 10 | | (14) Dextromoramide; | 11 | | (15) Diampromide; | 12 | | (16) Diethylthiambutene; | 13 | | (17) Difenoxin; | 14 | | (18) Dimenoxadol; | 15 | | (19) Dimepheptanol; | 16 | | (20) Dimethylthiambutene; | 17 | | (21) Dioxaphetylbutyrate; | 18 | | (22) Dipipanone; | 19 | | (23) Ethylmethylthiambutene; | 20 | | (24) Etonitazene; | 21 | | (25) Etoxeridine; | 22 | | (26) Furethidine; | 23 | | (26.1) Hydrocodone; | 24 | | (27) Hydroxpethidine; | 25 | | (28) Ketobemidone; | 26 | | (29) Levomoramide; |
| | | HB4707 | - 6 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (30) Levophenacylmorphan; | 2 | | (31) 3-Methylfentanyl
| 3 | | (N-[3-methyl-1-(2-phenylethyl)-
| 4 | | 4-piperidyl]-N-phenylpropanamide); | 5 | | (31.1) 3-Methylthiofentanyl
| 6 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 7 | | 4-piperidinyl]-N-phenylpropanamide); | 8 | | (32) Morpheridine; | 9 | | (33) Noracymethadol; | 10 | | (34) Norlevorphanol; | 11 | | (35) Normethadone; | 12 | | (36) Norpipanone; | 13 | | (36.1) Para-fluorofentanyl
| 14 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 15 | | 4-piperidinyl]propanamide); | 16 | | (37) Phenadoxone; | 17 | | (38) Phenampromide; | 18 | | (39) Phenomorphan; | 19 | | (40) Phenoperidine; | 20 | | (41) Piritramide; | 21 | | (42) Proheptazine; | 22 | | (43) Properidine; | 23 | | (44) Propiram; | 24 | | (45) Racemoramide; | 25 | | (45.1) Thiofentanyl
| 26 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
|
| | | HB4707 | - 7 - | LRB100 16559 RLC 31691 b |
|
| 1 | | 4-piperidinyl]-propanamide); | 2 | | (46) Tilidine; | 3 | | (47) Trimeperidine; | 4 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 5 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 6 | | N-phenylpropanamide); | 7 | | (49) Furanyl fentanyl (FU-F); | 8 | | (50) Butyryl fentanyl; | 9 | | (51) Valeryl fentanyl; | 10 | | (52) Acetyl fentanyl; | 11 | | (53) Beta-hydroxy-thiofentanyl; | 12 | | (54) 3,4-dichloro-N-[2-
| 13 | | (dimethylamino)cyclohexyl]-N-
| 14 | | methylbenzamide (U-47700); | 15 | | (55) 4-chloro-N-[1-[2-
| 16 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| 17 | | benzenesulfonamide (W-18); | 18 | | (56) 4-chloro-N-[1-(2-phenylethyl)
| 19 | | -2-piperidinylidene]-benzenesulfonamide (W-15); | 20 | | (57) acrylfentanyl (acryloylfentanyl). | 21 | | (c) Unless specifically excepted or unless listed in | 22 | | another
schedule, any of the following opium derivatives, its | 23 | | salts, isomers
and salts of isomers, whenever the existence of | 24 | | such salts, isomers and
salts of isomers is possible within the | 25 | | specific chemical designation: | 26 | | (1) Acetorphine; |
| | | HB4707 | - 8 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (2) Acetyldihydrocodeine; | 2 | | (3) Benzylmorphine; | 3 | | (4) Codeine methylbromide; | 4 | | (5) Codeine-N-Oxide; | 5 | | (6) Cyprenorphine; | 6 | | (7) Desomorphine; | 7 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 8 | | (9) Dihydromorphine; | 9 | | (10) Drotebanol; | 10 | | (11) Etorphine (except hydrochloride salt); | 11 | | (12) Heroin; | 12 | | (13) Hydromorphinol; | 13 | | (14) Methyldesorphine; | 14 | | (15) Methyldihydromorphine; | 15 | | (16) Morphine methylbromide; | 16 | | (17) Morphine methylsulfonate; | 17 | | (18) Morphine-N-Oxide; | 18 | | (19) Myrophine; | 19 | | (20) Nicocodeine; | 20 | | (21) Nicomorphine; | 21 | | (22) Normorphine; | 22 | | (23) Pholcodine; | 23 | | (24) Thebacon. | 24 | | (d) Unless specifically excepted or unless listed in | 25 | | another
schedule, any material, compound, mixture, or | 26 | | preparation which contains
any quantity of the following |
| | | HB4707 | - 9 - | LRB100 16559 RLC 31691 b |
|
| 1 | | hallucinogenic substances, or which
contains any of its salts, | 2 | | isomers and salts of isomers, whenever the
existence of such | 3 | | salts, isomers, and salts of isomers is possible
within the | 4 | | specific chemical designation (for the purposes of this
| 5 | | paragraph only, the term "isomer" includes the optical, | 6 | | position and
geometric isomers): | 7 | | (1) 3,4-methylenedioxyamphetamine
| 8 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 9 | | methylenedioxyamphetamine, MDA); | 10 | | (1.1) Alpha-ethyltryptamine
| 11 | | (some trade or other names: etryptamine;
| 12 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 13 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 14 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 15 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 16 | | (also known as: N-ethyl-alpha-methyl-
| 17 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 18 | | and MDEA); | 19 | | (2.2) N-Benzylpiperazine (BZP); | 20 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | 21 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 22 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 23 | | (5) (Blank); | 24 | | (6) Diethyltryptamine (DET); | 25 | | (7) Dimethyltryptamine (DMT); | 26 | | (7.1) 5-Methoxy-diallyltryptamine; |
| | | HB4707 | - 10 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 2 | | (9) Ibogaine (some trade and other names:
| 3 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 4 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 5 | | indole; Tabernanthe iboga); | 6 | | (10) Lysergic acid diethylamide; | 7 | | (10.1) Salvinorin A; | 8 | | (10.5) Salvia divinorum (meaning all parts of the plant | 9 | | presently classified
botanically as Salvia divinorum, | 10 | | whether growing or not, the
seeds thereof, any extract from | 11 | | any part of that plant, and every compound,
manufacture, | 12 | | salts, isomers, and salts of
isomers whenever the existence | 13 | | of such salts, isomers, and salts of
isomers is possible | 14 | | within the specific chemical designation, derivative, | 15 | | mixture, or preparation of that plant, its
seeds or | 16 | | extracts);
| 17 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 18 | | (12) Peyote (meaning all parts of the plant presently | 19 | | classified
botanically as Lophophora williamsii
Lemaire, | 20 | | whether growing or not, the
seeds thereof, any extract from | 21 | | any part of that plant, and every compound,
manufacture, | 22 | | salts, derivative, mixture, or preparation of that plant, | 23 | | its
seeds or extracts); | 24 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 25 | | (14) N-methyl-3-piperidyl benzilate; | 26 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
| | | HB4707 | - 11 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (also known as N-hydroxy-alpha-methyl-
| 2 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 3 | | (15) Parahexyl; some trade or other names:
| 4 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 5 | | dibenzo (b,d) pyran; Synhexyl; | 6 | | (16) Psilocybin; | 7 | | (17) Psilocyn; | 8 | | (18) Alpha-methyltryptamine (AMT); | 9 | | (19) 2,5-dimethoxyamphetamine
| 10 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 11 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 12 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 13 | | 4-bromo-2,5-DMA); | 14 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 15 | | Some trade or other names: 2-(4-bromo-
| 16 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 17 | | alpha-desmethyl DOB, 2CB, Nexus; | 18 | | (21) 4-methoxyamphetamine
| 19 | | (4-methoxy-alpha-methylphenethylamine;
| 20 | | paramethoxyamphetamine; PMA); | 21 | | (22) (Blank); | 22 | | (23) Ethylamine analog of phencyclidine.
| 23 | | Some trade or other names:
| 24 | | N-ethyl-1-phenylcyclohexylamine,
| 25 | | (1-phenylcyclohexyl) ethylamine,
| 26 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
| | | HB4707 | - 12 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 2 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 3 | | PHP; | 4 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 5 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 6 | | (another name: DOET); | 7 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 8 | | (another name: TCPy); | 9 | | (28) (Blank); | 10 | | (29) Thiophene analog of phencyclidine (some trade
| 11 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 12 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 13 | | (29.1) Benzothiophene analog of phencyclidine . Some | 14 | | trade or other names: BTCP or benocyclidine; | 15 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | 16 | | (30) Bufotenine (some trade or other names:
| 17 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 18 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 19 | | 5-hydroxy-N,N-dimethyltryptamine;
| 20 | | N,N-dimethylserotonin; mappine); | 21 | | (31) (Blank); | 22 | | (32) (Blank); | 23 | | (33) (Blank); | 24 | | (34) (Blank); | 25 | | (34.5) (Blank); | 26 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
| | | HB4707 | - 13 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (2-methyloctan-2-yl)-6a,7, | 2 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 3 | | Some trade or other names: HU-210; | 4 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 5 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 6 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 7 | | salts, and salts of isomers; Some trade or other | 8 | | names: HU-210, Dexanabinol; | 9 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 10 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 11 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 12 | | Some trade or other names: HU-211; | 13 | | (37) (Blank); | 14 | | (38) (Blank); | 15 | | (39) (Blank); | 16 | | (40) (Blank); | 17 | | (41) (Blank); | 18 | | (42) Any compound structurally derived from | 19 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane | 20 | | by substitution at the nitrogen atom of the indole ring by | 21 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 22 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 23 | | 1-(N-methyl-2-piperidinyl)methyl, or | 24 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 25 | | in the indole ring to any extent, whether or not | 26 | | substituted in the naphthyl ring to any extent. Examples of |
| | | HB4707 | - 14 - | LRB100 16559 RLC 31691 b |
|
| 1 | | this structural class include, but are not limited to, | 2 | | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | 3 | | (43) Any compound structurally derived from | 4 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 5 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 7 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | in the pyrrole ring to any extent, whether or not | 10 | | substituted in the naphthyl ring to any extent. Examples of | 11 | | this structural class include, but are not limited to, | 12 | | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | 13 | | (44) Any compound structurally derived from | 14 | | 1-(1-naphthylmethyl)indene by substitution at the | 15 | | 3-position of the indene ring by alkyl, haloalkyl, alkenyl, | 16 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 17 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 18 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 19 | | in the indene ring to any extent, whether or not | 20 | | substituted in the naphthyl ring to any extent. Examples of | 21 | | this structural class include, but are not limited to, | 22 | | JWH-176; | 23 | | (45) Any compound structurally derived from | 24 | | 3-phenylacetylindole by substitution at the nitrogen atom | 25 | | of the indole ring with alkyl, haloalkyl, alkenyl, | 26 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
| | | HB4707 | - 15 - | LRB100 16559 RLC 31691 b |
|
| 1 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 3 | | in the indole ring to any extent, whether or not | 4 | | substituted in the phenyl ring to any extent. Examples of | 5 | | this structural class include, but are not limited to, | 6 | | JWH-167, JWH-250, JWH-251, and RCS-8; | 7 | | (46) Any compound structurally derived from | 8 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 9 | | 5-position of the phenolic ring by alkyl, haloalkyl, | 10 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 11 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 12 | | 2-(4-morpholinyl)ethyl, whether or not substituted in the | 13 | | cyclohexyl ring to any extent. Examples of this structural | 14 | | class include, but are not limited to, CP 47, 497 and its | 15 | | C8 homologue (cannabicyclohexanol); | 16 | | (46.1) Any compound structurally derived from | 17 | | 3-(benzoyl) indole with substitution at the nitrogen atom | 18 | | of the indole ring by an alkyl, haloalkyl, alkenyl, | 19 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 20 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl group whether or not further | 22 | | substituted in the indole ring to any extent and whether or | 23 | | not substituted in the phenyl ring to any extent. Examples | 24 | | of this structural class include, but are not limited to, | 25 | | AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and | 26 | | RCS-4; |
| | | HB4707 | - 16 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (47) (Blank); | 2 | | (48) (Blank); | 3 | | (49) (Blank); | 4 | | (50) (Blank); | 5 | | (51) (Blank); | 6 | | (52) (Blank); | 7 | | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine . | 8 | | Some trade or other names: 2C-T-7; | 9 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine . Some trade | 10 | | or other names: 2C-E; | 11 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine . Some | 12 | | trade or other names: 2C-D; | 13 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine . Some | 14 | | trade or other names: 2C-C; | 15 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine . Some trade | 16 | | or other names: 2C-I; | 17 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine . Some | 18 | | trade or other names: 2C-T-2; | 19 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine . | 20 | | Some trade or other names: 2C-T-4; | 21 | | (53.7) 2,5-dimethoxyphenethylamine . Some trade or | 22 | | other names: 2C-H; | 23 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine . Some trade | 24 | | or other names: 2C-N; | 25 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine . Some | 26 | | trade or other names: 2C-P; |
| | | HB4707 | - 17 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine . Some | 2 | | trade or other names: 2C-G; | 3 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | 4 | | phenethylamine referred to in subparagraphs (20.1), (53), | 5 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | 6 | | (53.8), (53.9), and (53.10) including, but not limited to, | 7 | | 25I-NBOMe and 25C-NBOMe; | 8 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 9 | | (55) (Blank); | 10 | | (56) (Blank); | 11 | | (57) (Blank); | 12 | | (58) (Blank); | 13 | | (59) 3-cyclopropoylindole with substitution at the | 14 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 15 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 16 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indole ring to any extent, whether or not | 19 | | substituted on the cyclopropyl ring to any extent: | 20 | | including, but not limited to, XLR11, UR144, FUB-144; | 21 | | (60) 3-adamantoylindole with substitution at the | 22 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 23 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 24 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 26 | | on the indole ring to any extent, whether or not |
| | | HB4707 | - 18 - | LRB100 16559 RLC 31691 b |
|
| 1 | | substituted on the adamantyl ring to any extent: including, | 2 | | but not limited to, AB-001; | 3 | | (61) N-(adamantyl)-indole-3-carboxamide with | 4 | | substitution at the nitrogen atom of the indole ring by | 5 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 6 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 7 | | 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | on the indole ring to any extent, whether or not | 10 | | substituted on the adamantyl ring to any extent: including, | 11 | | but not limited to, APICA/2NE-1, STS-135; | 12 | | (62) N-(adamantyl)-indazole-3-carboxamide with | 13 | | substitution at a nitrogen atom of the indazole ring by | 14 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 15 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 16 | | 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indazole ring to any extent, whether or not | 19 | | substituted on the adamantyl ring to any extent: including, | 20 | | but not limited to, AKB48, 5F-AKB48; | 21 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | 22 | | with substitution at the nitrogen atom of the indole ring | 23 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 24 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 25 | | 1-(N-methyl-2-piperidinyl)methyl, or | 26 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
| | | HB4707 | - 19 - | LRB100 16559 RLC 31691 b |
|
| 1 | | on the indole ring to any extent, whether or not | 2 | | substituted on the quinoline ring to any extent: including, | 3 | | but not limited to, PB22, 5F-PB22, FUB-PB-22; | 4 | | (64) 3-(1-naphthoyl)indazole with substitution at the | 5 | | nitrogen atom of the indazole ring by alkyl, haloalkyl, | 6 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 7 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | on the indazole ring to any extent, whether or not | 10 | | substituted on the naphthyl ring to any extent: including, | 11 | | but not limited to, THJ-018, THJ-2201; | 12 | | (65) 2-(1-naphthoyl)benzimidazole with substitution at | 13 | | the nitrogen atom of the benzimidazole ring by alkyl, | 14 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 15 | | aryl halide, alkyl aryl halide, | 16 | | 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the benzimidazole ring to any extent, whether or not | 19 | | substituted on the naphthyl ring to any extent: including, | 20 | | but not limited to, FUBIMINA; | 21 | | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | 22 | | 3-carboxamide with substitution on the nitrogen atom of the | 23 | | indazole ring by alkyl, haloalkyl, alkenyl, | 24 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 25 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 26 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
| | | HB4707 | - 20 - | LRB100 16559 RLC 31691 b |
|
| 1 | | on the indazole ring to any extent: including, but not | 2 | | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 3 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 4 | | indazole-3-carboxamide with substitution on the nitrogen | 5 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 7 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | on the indazole ring to any extent: including, but not | 10 | | limited to, ADB-PINACA, ADB-FUBINACA; | 11 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 12 | | indole-3-carboxamide with substitution on the nitrogen | 13 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 14 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 15 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 16 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 17 | | on the indole ring to any extent: including, but not | 18 | | limited to, ADBICA, 5F-ADBICA; | 19 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | 20 | | 3-carboxamide with substitution on the nitrogen atom of the | 21 | | indole ring by alkyl, haloalkyl, alkenyl, | 22 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 23 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 24 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 25 | | on the indole ring to any extent: including, but not | 26 | | limited to, ABICA, 5F-ABICA; |
| | | HB4707 | - 21 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | 2 | | methylbutanoate with substitution on the nitrogen atom of | 3 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 4 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 5 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 6 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 7 | | on the indazole ring to any extent: including, but not | 8 | | limited to, AMB, 5F-AMB ; . | 9 | | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | 10 | | dimethylbutanoate with substitution on the nitrogen
atom | 11 | | of the indazole ring by alkyl, haloalkyl, alkenyl,
| 12 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl | 13 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 14 | | 2-(4-morpholinyl)ethyl, whether or not further substituted
| 15 | | on the indazole ring to any extent: including, but not
| 16 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | 17 | | (72) Methyl 2-(1H-indole-3-carboxamido)-3- | 18 | | methylbutanoate with substitution on the nitrogen atom
of | 19 | | the indole ring by alkyl, haloalkyl, alkenyl,
| 20 | | cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl | 21 | | halide, 1-(N-methyl-2-piperidinyl)methyl,
or | 22 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted | 23 | | on the indazole ring to any extent:
including, but not | 24 | | limited to, MMB018, MMB2201,
and AMB-CHMICA; | 25 | | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | 26 | | dimethylbutanoate with substitution
on the nitrogen atom |
| | | HB4707 | - 22 - | LRB100 16559 RLC 31691 b |
|
| 1 | | of the indole ring by alkyl,
haloalkyl, alkenyl, | 2 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | 3 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 4 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted | 5 | | on the
indazole ring to any extent: including, but
not | 6 | | limited to, MDMB-CHMICA; | 7 | | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | 8 | | indazole-3-carboxamide with
substitution on the nitrogen | 9 | | atom of the indazole
ring by alkyl, haloalkyl, alkenyl, | 10 | | cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl | 11 | | halide,
1-(N-methyl-2-piperidinyl)methyl, or | 12 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted | 13 | | on the indazole ring to any
extent: including, but not | 14 | | limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; | 15 | | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | 16 | | 3-carboxamide with substitution on
the nitrogen atom of the | 17 | | indole ring by alkyl,
haloalkyl, alkenyl, | 18 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | 19 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 20 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted | 21 | | on the indazole
ring to any extent: including, but not | 22 | | limited to,
APP-PICA and 5-fluoro-APP-PICA; | 23 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 24 | | 4-AcO-DMT; | 25 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | 26 | | name 5-MeO-MIPT; |
| | | HB4707 | - 23 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | 2 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | 3 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | 4 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| 5 | | (4-HO-MiPT); | 6 | | (82) Fluorophenylpiperazine; | 7 | | (83) Methoxetamine; | 8 | | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | 9 | | ethcathinone). | 10 | | (e) Unless specifically excepted or unless listed in | 11 | | another
schedule, any material, compound, mixture, or | 12 | | preparation which contains
any quantity of the following | 13 | | substances having a depressant effect on
the central nervous | 14 | | system, including its salts, isomers, and salts of
isomers | 15 | | whenever the existence of such salts, isomers, and salts of
| 16 | | isomers is possible within the specific chemical designation: | 17 | | (1) mecloqualone; | 18 | | (2) methaqualone; and | 19 | | (3) gamma hydroxybutyric acid. | 20 | | (f) Unless specifically excepted or unless listed in | 21 | | another schedule,
any material, compound, mixture, or | 22 | | preparation which contains any quantity
of the following | 23 | | substances having a stimulant effect on the central nervous
| 24 | | system, including its salts, isomers, and salts of isomers: | 25 | | (1) Fenethylline; | 26 | | (2) N-ethylamphetamine; |
| | | HB4707 | - 24 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (3) Aminorex (some other names:
| 2 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 3 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 4 | | salts, optical isomers, and salts of optical isomers; | 5 | | (4) Methcathinone (some other names:
| 6 | | 2-methylamino-1-phenylpropan-1-one;
| 7 | | Ephedrone; 2-(methylamino)-propiophenone;
| 8 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 9 | | methycathinone; Monomethylpropion; UR 1431) and its
| 10 | | salts, optical isomers, and salts of optical isomers; | 11 | | (5) Cathinone (some trade or other names:
| 12 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 13 | | 2-amino-1-phenyl-propanone; norephedrone); | 14 | | (6) N,N-dimethylamphetamine (also known as:
| 15 | | N,N-alpha-trimethyl-benzeneethanamine;
| 16 | | N,N-alpha-trimethylphenethylamine); | 17 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 18 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 19 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | 20 | | (9) Halogenated amphetamines and
| 21 | | methamphetamines - any compound derived from either
| 22 | | amphetamine or methamphetamine through the substitution
| 23 | | of a halogen on the phenyl ring, including, but not
| 24 | | limited to, 2-fluoroamphetamine, 3-
| 25 | | fluoroamphetamine and 4-fluoroamphetamine; | 26 | | (10) Aminopropylbenzofuran (APB):
|
| | | HB4707 | - 25 - | LRB100 16559 RLC 31691 b |
|
| 1 | | including 4-(2-Aminopropyl) benzofuran, 5-
| 2 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| 3 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; | 4 | | (11) Aminopropyldihydrobenzofuran (APDB):
| 5 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 6 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 7 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| 8 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | 9 | | (12) Methylaminopropylbenzofuran
| 10 | | (MAPB): including 4-(2-methylaminopropyl)
| 11 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 12 | | 6-(2-methylaminopropyl)benzofuran
| 13 | | and 7-(2-methylaminopropyl)benzofuran. | 14 | | (g) Temporary listing of substances subject to emergency | 15 | | scheduling.
Any material, compound, mixture, or preparation | 16 | | that contains any quantity
of the following substances: | 17 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| 18 | | (benzylfentanyl), its optical isomers, isomers, salts,
and | 19 | | salts of isomers; | 20 | | (2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- | 21 | | phenylpropanamide (thenylfentanyl),
its optical isomers, | 22 | | salts, and salts of isomers. | 23 | | (h) Synthetic cathinones. Unless specifically excepted, | 24 | | any chemical compound which is not approved by the United | 25 | | States Food and Drug Administration or, if approved, is not | 26 | | dispensed or possessed in accordance with State or federal law, |
| | | HB4707 | - 26 - | LRB100 16559 RLC 31691 b |
|
| 1 | | not including bupropion, structurally derived from | 2 | | 2-aminopropan-1-one by substitution at the 1-position with | 3 | | either phenyl, naphthyl, or thiophene ring systems, whether or | 4 | | not the compound is further modified in one or more of the | 5 | | following ways: | 6 | | (1) by substitution in the ring system to any extent | 7 | | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | 8 | | halide substituents, whether or not further substituted in | 9 | | the ring system by one or more other univalent | 10 | | substituents. Examples of this class include, but are not | 11 | | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | 12 | | (2) by substitution at the 3-position with an acyclic | 13 | | alkyl substituent. Examples of this class include, but are | 14 | | not limited to, 2-methylamino-1-phenylbutan-1-one | 15 | | (buphedrone); or | 16 | | (3) by substitution at the 2-amino nitrogen atom with | 17 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | 18 | | inclusion of the 2-amino nitrogen atom in a cyclic | 19 | | structure. Examples of this class include, but are not | 20 | | limited to, Dimethylcathinone, Ethcathinone, and | 21 | | a-Pyrrolidinopropiophenone (a-PPP). | 22 | | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | 23 | | 100-368, eff. 1-1-18; revised 10-5-17.)
| 24 | | (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
| 25 | | Sec. 206. (a) The controlled substances listed in this |
| | | HB4707 | - 27 - | LRB100 16559 RLC 31691 b |
|
| 1 | | Section are
included in Schedule II.
| 2 | | (b) Unless specifically excepted or unless listed in | 3 | | another
schedule, any of the following substances whether | 4 | | produced directly or
indirectly by extraction from substances | 5 | | of vegetable origin, or
independently by means of chemical | 6 | | synthesis, or by combination of
extraction and chemical | 7 | | synthesis:
| 8 | | (1) Opium and opiates, and any salt, compound, | 9 | | derivative or
preparation of opium or opiate, excluding | 10 | | apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, | 11 | | nalmefene, naloxone, and naltrexone, and their respective
| 12 | | salts, but including the following:
| 13 | | (i) Raw Opium;
| 14 | | (ii) Opium extracts;
| 15 | | (iii) Opium fluid extracts;
| 16 | | (iv) Powdered opium;
| 17 | | (v) Granulated opium;
| 18 | | (vi) Tincture of opium;
| 19 | | (vii) Codeine;
| 20 | | (viii) Ethylmorphine;
| 21 | | (ix) Etorphine Hydrochloride;
| 22 | | (x) (Blank); Hydrocodone;
| 23 | | (xi) Hydromorphone;
| 24 | | (xii) Metopon;
| 25 | | (xiii) Morphine;
| 26 | | (xiii.5) 6-Monoacetylmorphine; |
| | | HB4707 | - 28 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (xiv) Oxycodone;
| 2 | | (xv) Oxymorphone;
| 3 | | (xv.5) Tapentadol; | 4 | | (xvi) Thebaine;
| 5 | | (xvii) Thebaine-derived butorphanol.
| 6 | | (xviii) Methorphan, except drug products | 7 | | containing dextromethorphan that may be dispensed | 8 | | pursuant to a prescription order of a practitioner and | 9 | | are sold in compliance with the safety and labeling | 10 | | standards as set forth by the United States Food and | 11 | | Drug Administration, or drug products containing | 12 | | dextromethorphan that are sold in solid, tablet, | 13 | | liquid, capsule, powder, thin film, or gel form and | 14 | | which are formulated, packaged, and sold in dosages and | 15 | | concentrations for use as an over-the-counter drug | 16 | | product. For the purposes of this Section, | 17 | | "over-the-counter drug product" means a drug that is | 18 | | available to consumers without a prescription and sold | 19 | | in compliance with the safety and labeling standards as | 20 | | set forth by the United States Food and Drug | 21 | | Administration.
| 22 | | (2) Any salt, compound, isomer, derivative or | 23 | | preparation thereof
which is chemically equivalent or | 24 | | identical with any of the substances
referred to in | 25 | | subparagraph (1), but not including the isoquinoline
| 26 | | alkaloids of opium;
|
| | | HB4707 | - 29 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (3) Opium poppy and poppy straw;
| 2 | | (4) Coca leaves and any salt, compound, isomer, salt of | 3 | | an isomer,
derivative, or preparation of coca leaves | 4 | | including cocaine or ecgonine,
and any salt, compound, | 5 | | isomer, derivative, or preparation thereof which is
| 6 | | chemically equivalent or identical with any of these | 7 | | substances, but not
including decocainized coca leaves or | 8 | | extractions of coca leaves which do
not contain cocaine or | 9 | | ecgonine (for the purpose of this paragraph, the
term | 10 | | "isomer" includes optical, positional and geometric | 11 | | isomers);
| 12 | | (5) Concentrate of poppy straw (the crude extract of | 13 | | poppy straw in
either liquid, solid or powder form which | 14 | | contains the phenanthrine
alkaloids of the opium poppy).
| 15 | | (c) Unless specifically excepted or unless listed in | 16 | | another
schedule any of the following opiates, including their | 17 | | isomers, esters,
ethers, salts, and salts of isomers, whenever | 18 | | the existence of these
isomers, esters, ethers and salts is | 19 | | possible within the specific
chemical designation, dextrorphan | 20 | | excepted:
| 21 | | (1) Alfentanil;
| 22 | | (1.1) Carfentanil;
| 23 | | (1.2) Thiafentanyl; | 24 | | (2) Alphaprodine;
| 25 | | (3) Anileridine;
| 26 | | (4) Bezitramide;
|
| | | HB4707 | - 30 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (5) Bulk Dextropropoxyphene (non-dosage forms);
| 2 | | (6) Dihydrocodeine;
| 3 | | (7) Diphenoxylate;
| 4 | | (8) Fentanyl;
| 5 | | (9) Sufentanil;
| 6 | | (9.5) Remifentanil;
| 7 | | (10) Isomethadone;
| 8 | | (11) (Blank);
| 9 | | (12) Levorphanol (Levorphan);
| 10 | | (13) Metazocine;
| 11 | | (14) Methadone;
| 12 | | (15) Methadone-Intermediate,
| 13 | | 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
| 14 | | (16) Moramide-Intermediate,
| 15 | | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
| 16 | | acid;
| 17 | | (17) Pethidine (meperidine);
| 18 | | (18) Pethidine-Intermediate-A,
| 19 | | 4-cyano-1-methyl-4-phenylpiperidine;
| 20 | | (19) Pethidine-Intermediate-B,
| 21 | | ethyl-4-phenylpiperidine-4-carboxylate;
| 22 | | (20) Pethidine-Intermediate-C,
| 23 | | 1-methyl-4-phenylpiperidine-4-carboxylic acid;
| 24 | | (21) Phenazocine;
| 25 | | (22) Piminodine;
| 26 | | (23) Racemethorphan;
|
| | | HB4707 | - 31 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (24) (Blank);
| 2 | | (25) Levo-alphacetylmethadol (some other names:
| 3 | | levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
| 4 | | (d) Unless specifically excepted or unless listed in | 5 | | another
schedule, any material, compound, mixture, or | 6 | | preparation which contains
any quantity of the following | 7 | | substances having a stimulant effect on
the central nervous | 8 | | system:
| 9 | | (1) Amphetamine, its salts, optical isomers, and salts | 10 | | of its
optical isomers;
| 11 | | (2) Methamphetamine, its salts, isomers, and salts of | 12 | | its isomers;
| 13 | | (3) Phenmetrazine and its salts;
| 14 | | (4) Methylphenidate;
| 15 | | (5) Lisdexamfetamine. | 16 | | (e) Unless specifically excepted or unless listed in | 17 | | another
schedule, any material, compound, mixture, or | 18 | | preparation which contains
any quantity of the following | 19 | | substances having a depressant effect on
the central nervous | 20 | | system, including its salts, isomers, and salts of
isomers | 21 | | whenever the existence of such salts, isomers, and salts of
| 22 | | isomers is possible within the specific chemical designation:
| 23 | | (1) Amobarbital;
| 24 | | (2) Secobarbital;
| 25 | | (3) Pentobarbital;
| 26 | | (4) Pentazocine;
|
| | | HB4707 | - 32 - | LRB100 16559 RLC 31691 b |
|
| 1 | | (5) Phencyclidine;
| 2 | | (6) Gluthethimide;
| 3 | | (7) (Blank).
| 4 | | (f) Unless specifically excepted or unless listed in | 5 | | another schedule,
any material, compound, mixture, or | 6 | | preparation which contains any quantity
of the following | 7 | | substances:
| 8 | | (1) Immediate precursor to amphetamine and | 9 | | methamphetamine:
| 10 | | (i) Phenylacetone
| 11 | | Some trade or other names: phenyl-2-propanone;
| 12 | | P2P; benzyl methyl ketone; methyl benzyl ketone.
| 13 | | (2) Immediate precursors to phencyclidine:
| 14 | | (i) 1-phenylcyclohexylamine;
| 15 | | (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
| 16 | | (3) Nabilone.
| 17 | | (Source: P.A. 100-368, eff. 1-1-18 .)
|
|